MedTrace Logo

Glycosaminoglycan Scores as Monitoring Biomarkers in Confined Renal Cell Carcinoma

NCT02732652 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2023-03-22

No results posted yet for this study

Summary

In this study, a score based on glycosaminoglycan (GAG) profiling in subjects with suspicion of renal cell carcinoma (RCC) is hypothesized to distinguish malignant masses when early actionable clinical decisions are desirable. For example to diagnose early recurrence after surgical treatment; to screen population at risk of RCC; or to distinguish benign masses from RCC before surgical treatment. To this end, plasma and urine GAGs will be measured in a prospective cohort of patients referred to surgical treatment for RCC. The resulting GAG scores are then correlated to post-surgical recurrence, to post-surgical definitive diagnosis and and to tumor size if RCC. In a subset cohort of patients at high risk of RCC recurrence, plasma and urine GAGs will be monitored to observe its correlation with disease recurrence.

Conditions

  • Carcinoma, Renal Cell

Sponsors & Collaborators

  • Sahlgrenska University Hospital

    collaborator OTHER

  • Chalmers University of Technology

    lead OTHER

Principal Investigators

  • Jens Nielsen, PhD · Chalmers University of Technology

  • Sven Lundstam, M.D. PhD · Sahlgrenska University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2021-05-31
Completion
2021-09-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02732652 on ClinicalTrials.gov